BioSpace News Archive

Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.

Daiichi Sankyo Company, Limited announced that ENHERTU®, a HER2 directed antibody drug conjugate, received the Prime Minister’s Award at the 9th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company’s board of directors

Spectrum Solutions, LLC today announced its sponsored research collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today that it has successfully completed the first human use of its Amplifi™ Vein Dilation System.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today confirmed that the Company is in discussion with the U.S. government to purchase an additional 100 million doses of the Moderna COVID-19 Vaccine for delivery in the third quarter of 2021.

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, including a Phase 2 ready norovirus program, announced today health care economic findings published in the American Journal of Preventative Medicine.

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for KP879 (KP879 IND)

Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data, the FDA’s feedback will allow the Company to apply for a limited clinical investigation known as an Early Feasibility Study (EFS), which is designed for novel technologies such as the SCS. Consequently, the Company rei

Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Melissa L. Gilliam, M.D., M.P.H., to its Board of Directors.